Trial Profile

A Phase II, Double-blind, Dose-Ranging, Parallel, Long-term Extension Study to Evaluate the Safety and Efficacy of Enpatoran in Participants With Subacute Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus and/or Systemic Lupus Erythematosus Having Completed the WILLOW (MS200569-0003) Study Treatment (WILLOW LTE)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enpatoran (Primary)
Indications Cutaneous lupus erythematosus; Discoid lupus erythematosus; Systemic lupus erythematosus
Focus Adverse reactions
Acronyms WILLOW LTE
Sponsors Merck KGaA

02 Jul 2025 Planned End Date changed from 15 Apr 2025 to 12 Aug 2028.
02 Jul 2025 Planned primary completion date changed from 15 Apr 2025 to 12 Aug 2028.
02 Jul 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com